Key result
Higher Naples Prognostic Score linked to ~3.4-fold higher in-hospital mortality in type 2 cardiorenal syndrome.
Why the study?
The association between admission Naples Prognostic Score and in-hospital mortality in patients with type 2 cardiorenal syndrome was not established.
Does the admission Naples Prognostic Score predict in-hospital mortality in adults with type 2 cardiorenal syndrome?
Cohort (n=101)
No
Does the admission Naples Prognostic Score predict in-hospital mortality in adults with type 2 cardiorenal syndrome?
Odds Ratio: 3.42 (95% CI 1.76–7.77)
Absolute Event Rate: 46.2% vs 4.1%
p-value: p=<0.001
Higher admission Naples Prognostic Score is significantly associated with increased in-hospital mortality in patients with type 2 cardiorenal syndrome.
May support NPS for risk stratification in type 2 cardiorenal syndrome; hypothesis-generating and requires prospective validation before clinical adoption.
Objective: This study evaluated the association between admission Naples Prognostic Score (NPS) and in-hospital mortality in patients with clinical features consistent with type 2 cardiorenal syndrome (CRS-2). Methods: This retrospective, single-center study included 101 adults hospitalized for decompensated heart failure at Sakarya University Training and Research Hospital between June 2021 and August 2024. CRS-2 classification relied on nephrologist review of historical records. Admission NPS combined albumin, total cholesterol, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio. NPS was analyzed primarily as a continuous score using univariable and multivariable Firth penalized logistic regression with profile penalized-likelihood confidence intervals. Low (0–2) versus high (3–4) NPS comparisons were exploratory; no patient scored 0. Results: Overall, 26 patients (25.7%) died. Mortality was higher in the high-NPS than the low-NPS group (24/52 [46.2%] versus 2/49 [4.1%]; p < 0.001). After adjustment for age, New York Heart Association (NYHA) functional class, and left ventricular ejection fraction (LVEF), the odds ratio per one-point NPS increase was 3.42 (95% confidence interval [CI], 1.76–7.77; p < 0.001). The area under the receiver operating characteristic curve was 0.825 (percentile bootstrap 95% CI, 0.744–0.896). At the established NPS ≥ 3 category boundary, sensitivity was 92.3% (95% CI, 75.9–97.9%) and specificity was 62.7% (95% CI, 51.4–72.7%). Performance was estimated within the same cohort without optimism correction or external validation. Conclusions: Higher admission NPS was associated with in-hospital mortality after adjustment for age, NYHA class, and LVEF. These exploratory findings require external validation and assessment of incremental predictive value and clinical utility.
No takes yet. Share an insight, caveat, or question.
Eynel et al. (2026) conducted a cohort in Type 2 cardiorenal syndrome (CRS-2) (n=101). Naples Prognostic Score (NPS) vs. Low NPS (0-2) or per one-point increase was evaluated on In-hospital mortality (OR 3.42, 95% CI 1.76-7.77, p=<0.001). A higher admission Naples Prognostic Score was associated with increased in-hospital mortality in patients with type 2 cardiorenal syndrome (OR 3.42 per one-point increase; 95% CI 1.76-7.77; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: